| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$5 |
Trading Update and Growth Outlook
|
27 Feb 2026 9:08AM |
$0.016 |
$0.004 |
fallen by
78.13%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- $2.5 million contract with SynCardia for artificial heart development.
- Quarter to date sales of $3.7 million, mainly from new international clients.
- Potential future revenues of ~$40 million over 2-3 years.
- Cash on hand is $0.6 million with support via a $2.2 million Letter of Comfort.
- Focus on developing safety-critical medical devices.
- Continued management of operating expenses to support growth.
- Progress in commercial discussions for a cardiac monitoring platform.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Chimeric Therapeutics Limited (CHM) ORDINARY FULLY PAID |
Health Care |
$1 |
Portfolio streamlined - return of CHM CLTX to City of Hope
|
27 Feb 2026 9:08AM |
$0.002 |
$0.011 |
risen by
450%
|
|
CHM - Price-sensitive ASX Announcement
Full Release
Key Points
- Chimeric returns CHM CLTX asset to City of Hope.
- Strategic focus shifts to CHM CDH17 program.
- Decision aligns with disciplined capital management.
- CHM CLTX development was overtaken by other assets.
- City of Hope regains control of CHM CLTX intellectual property.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$5 |
Half Yearly Report and Accounts
|
27 Feb 2026 9:07AM |
$0.016 |
$0.004 |
fallen by
78.13%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss of $2,340,411 for the half-year ended 31 December 2025
- Comprehensive loss totaled $2,350,797
- Revenue from contracts with customers was $4,837,519
- Significant operating expenses and cash flow challenges
- Cash used in operations was $22,383
- Directors acknowledge material uncertainties regarding going concern
- Strategic initiatives for liquidity and capital management are underway
- Hydrix Ventures' investment portfolio valued at $2.7 million
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Wisetech Global Limited (WTC) ORDINARY FULLY PAID |
Information Technology |
$13,580 |
Application for quotation of securities - WTC
|
27 Feb 2026 9:07AM |
$49.000 |
$40.380 |
fallen by
17.59%
|
|
| Alcoa Corporation (AAI) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$18,301 |
ASX Listing Rule 1.15.3 Confirmation
|
27 Feb 2026 9:07AM |
$90.430 |
$69.350 |
fallen by
23.31%
|
|
| Harvey Norman Holdings Ltd (HVN) ORDINARY FULLY PAID |
Consumer Discretionary |
$5,333 |
Dividend/Distribution - HVN
|
27 Feb 2026 9:07AM |
$6.330 |
$4.280 |
fallen by
32.39%
|
|
| Harvey Norman Holdings Ltd (HVN) ORDINARY FULLY PAID |
Consumer Discretionary |
$5,333 |
Presentation of Results 1H26
|
27 Feb 2026 9:07AM |
$6.330 |
$4.280 |
fallen by
32.39%
|
|
HVN - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit Before Tax increased by 16.5% reaching $466.31 million compared to 1H25.
- Total system sales revenue grew by 6.9% to $5.16 billion.
- Australian franchisee sales rose by 4.8% to $3.50 billion.
- Overseas retail sales increased by 11.6% to $1.66 billion.
- Property segment PBT increased by 7.8% due to revaluation increments and rental growth.
- Total assets increased to $8.77 billion as of December 31, 2025.
- Net debt-to-equity ratio remains low at 13.02%.
- Continued investment in new stores and digital transformation, with expansions in UK and Malaysia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alcoa Corporation (AAI) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$18,301 |
Annual Report on Form 10-K for year ended December 31, 2025
|
27 Feb 2026 9:06AM |
$90.430 |
$69.350 |
fallen by
23.31%
|
|
| Titomic Limited (TTT) ORDINARY FULLY PAID |
Materials |
$273 |
Titomic Investor Day in Huntsville
|
27 Feb 2026 9:06AM |
$0.200 |
$0.170 |
fallen by
15%
|
|
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$27 |
At-the-Market (ATM) agreement with Acuity Capital
|
27 Feb 2026 9:06AM |
$0.065 |
$0.089 |
risen by
36.92%
|
|
NOX - Price-sensitive ASX Announcement
Full Release
Key Points
- Noxopharm Limited (ASX:NOX) has signed an At-the-Market (ATM) Agreement with Acuity Capital.
- The ATM provides up to $5 million of standby equity capital available to Noxopharm over the next five years until 31 July 2031.
- Noxopharm has full discretion on whether to use the ATM, including the number of shares issued and the minimum issue price.
- The company can set a price floor, with the final issue price being the greater of the floor price or up to a 10% discount to the Volume Weighted Average Price (VWAP).
- Noxopharm has placed 15,000,000 fully paid ordinary NOX ASX shares as security for the ATM at nil cash consideration.
- Noxopharm can buy back and cancel these shares, subject to shareholder approval, if the ATM is terminated early or upon maturity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Harvey Norman Holdings Ltd (HVN) ORDINARY FULLY PAID |
Consumer Discretionary |
$5,333 |
Results Announcement 1H26
|
27 Feb 2026 9:06AM |
$6.330 |
$4.280 |
fallen by
32.39%
|
|
HVN - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit before tax increased by 16.5% to $466.31 million.
- System sales revenue grew by 6.9% to $5.16 billion.
- Australian franchisee sales increased by 4.8%.
- Company-operated sales rose by 11.6%.
- Franchising operations profit before tax increased by 14.2%.
- Overseas retail segment profit before tax increased by 35.6%.
- Strong performances noted in New Zealand, Ireland, Slovenia, Croatia, Singapore, and Malaysia.
- Operating expenses reduced to 17.8% of system sales.
- Property segment profit before tax increased by 7.8%.
- Balance sheet strengthened with increased assets and conservative gearing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Titomic Limited (TTT) ORDINARY FULLY PAID |
Materials |
$273 |
Appendix 4G and Corporate Governance Statement
|
27 Feb 2026 9:06AM |
$0.200 |
$0.170 |
fallen by
15%
|
|
| Harvey Norman Holdings Ltd (HVN) ORDINARY FULLY PAID |
Consumer Discretionary |
$5,333 |
Half Yearly Report and Accounts
|
27 Feb 2026 9:06AM |
$6.330 |
$4.280 |
fallen by
32.39%
|
|
HVN - Price-sensitive ASX Announcement
Full Release
Key Points
- System sales growth of 6.9% to $5.16 billion.
- Company-operated sales revenue increased by 11.6% to $1.66 billion.
- Aggregated headline franchisee sales revenue rose by 4.8% to $3.50 billion.
- Profit Before Tax increased by 16.5% to $466.31 million.
- PBT excluding AASB 16 and property revaluations up by 20.1% to $372.79 million.
- International operations account for 25% of total PBT excluding property revaluations.
- Low net debt to equity ratio of 13.02%.
- Ample cash reserves with operating cash flows of $392.88 million.
- Interim dividend per share increased by 20.8% to 14.5 cents.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| archTIS Limited (AR9) ORDINARY FULLY PAID |
Information Technology |
$21 |
Appendix 4D and Half Year Report
|
27 Feb 2026 9:06AM |
$0.090 |
$0.044 |
fallen by
51.11%
|
|
AR9 - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for the half-year was $6,085,350, an increase from $2,769,834 in the prior period.
- The company reported a total comprehensive loss of $7,199,095 for the period.
- Significant investments were made in intangible assets, with the total reaching $29,705,853.
- Net cash used in operating activities was $6,273,992.
- The company raised $27,962,655 through the issue of shares.
- The report includes detailed financial statements, including profit or loss, cash flows, and changes in equity.
- archTIS Limited operates in the software and services sector related to information management and security.
- The cash balance as of December 31, 2025, was $6,488,262.
- The company's directors include Dr. Miles Jakeman AM, Dr. Marcus Thompson AM, and Mr. Daniel Lai.
- The financial report was prepared in accordance with Australian Accounting Standards.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Wisetech Global Limited (WTC) ORDINARY FULLY PAID |
Information Technology |
$13,580 |
WiseTech CEO share purchase
|
27 Feb 2026 9:05AM |
$49.000 |
$40.380 |
fallen by
17.59%
|
|
| Heavy Rare Earths Limited (HRE) ORDINARY FULLY PAID |
Materials |
$11 |
Change of Director's Interest Notice
|
27 Feb 2026 9:04AM |
$0.043 |
$0.047 |
risen by
9.30%
|
|
| Bougainville Copper Limited (BOC) 1 KINA ORDINARY FULLY PAID |
Materials |
$64 |
Initial Director's Interest Notice - Sir Moi Avei
|
27 Feb 2026 9:04AM |
$0.870 |
$0.160 |
fallen by
81.61%
|
|
| Jupiter Mines Limited. (JMS) ORDINARY FULLY PAID |
Materials |
$511 |
Half-Year Report and Appendix 4D-31 December 2025
|
27 Feb 2026 9:04AM |
$0.300 |
$0.260 |
fallen by
13.33%
|
|
JMS - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit after tax increased to $16.2 million for HY2026.
- Tshipi recorded a net profit after tax of ZAR369 million.
- Total manganese ore produced during the period was 1.7 million tonnes.
- Jupiter secured a 10-year MECA 3 Agreement with Transnet.
- Tshipi achieved Level 1 Broad-Based Black Economic Empowerment status.
- Exxaro Resources Limited acquired a 50.1% interest in Tshipi.
- Revenue remained stable at $4.3 million.
- Strategic focus on logistics capacity and sustainability.
- Cash and cash equivalents at the end of the period were $11.4 million.
- Directors declared a final dividend of 0.0075 per share.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Titomic Limited (TTT) ORDINARY FULLY PAID |
Materials |
$273 |
Results Release
|
27 Feb 2026 9:03AM |
$0.200 |
$0.170 |
fallen by
15%
|
|
| Astron Corporation Limited (ATR) ORDINARY FULLY PAID |
Materials |
$215 |
Financial Statements - half year ended 31 December 2025
|
27 Feb 2026 9:03AM |
$0.610 |
$0.500 |
fallen by
18.03%
|
|
| Titomic Limited (TTT) ORDINARY FULLY PAID |
Materials |
$273 |
Annual Report to Shareholders
|
27 Feb 2026 9:03AM |
$0.200 |
$0.170 |
fallen by
15%
|
|
| Nexsen Limited (NXN) ORDINARY FULLY PAID |
Health Care |
$19 |
Change in substantial holding - Nexsen
|
27 Feb 2026 9:03AM |
$0.160 |
$0.200 |
risen by
25%
|
|
| Nimy Resources Limited (NIM) ORDINARY FULLY PAID |
Materials |
$16 |
Nimy to join W.A. Critical Mineral Delegation to the U.S.
|
27 Feb 2026 9:03AM |
$0.061 |
$0.046 |
fallen by
24.59%
|
|
NIM - Price-sensitive ASX Announcement
Full Release
Key Points
- Nimy Resources will join the WA Government's Critical Minerals and Energy Partnerships Trade Mission to the U.S.
- The mission is led by WA Mines and Petroleum Minister David Michael.
- Nimy aims to discuss its Mons Gallium Block 3 resource with U.S. investors, financiers, and customers.
- The purpose is to strengthen critical minerals partnerships and build on the Australia-U.S. critical minerals framework.
- The mission includes meetings in New York and Washington DC.
- Nimy is positioned to leverage the growing commercial ties with North America.
- Nimy's Mons Gallium Block 3 hosts a JORC Inferred Resource with significant gallium and rare earth oxides.
- The delegation seeks to address the gallium shortage exacerbated by China's export controls.
- A scoping study on the Mons Gallium Block 3 project is underway and expected to complete in the second quarter of 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mesoblast Limited (MSB) ORDINARY FULLY PAID |
Health Care |
$3,065 |
Ryoncil Profits Underpinning Substantial Growth Pipeline
|
27 Feb 2026 9:02AM |
$2.420 |
$2.360 |
fallen by
2.48%
|
|
MSB - Price-sensitive ASX Announcement
Full Release
Key Points
- Successful U.S. commercial launch of Ryoncil® generated significant revenue growth.
- Ryoncil® gross sales reached US$57.0 million, with revenue of US$48.7 million after adjustments.
- Net loss improved to US$40.2 million compared to US$47.9 million in the previous year.
- Ryoncil® covered by both government and commercial payers, extending to 280 million U.S. lives.
- Mesoblast aims to expand Ryoncil® indications for lifecycle extension in adults and children.
- Phase 3 trial for Ryoncil® as second-line treatment for adults with SR-aGvHD is planned.
- Positive feedback received from FDA for Ryoncil® and rexlemestrocel-L trials.
- Financial stability supported by US$125.0 million non-dilutive credit-line facility.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Titomic Limited (TTT) ORDINARY FULLY PAID |
Materials |
$273 |
Appendix 4E
|
27 Feb 2026 9:01AM |
$0.200 |
$0.170 |
fallen by
15%
|
|
TTT - Price-sensitive ASX Announcement
Full Release
Key Points
- Titomic Limited's Appendix 4E financial report.
- Reporting period: six months ending 31 December 2025.
- Revenue decrease by 44.1% to $5.27 million.
- Loss after tax decrease by 10.2% to $17.85 million.
- No dividends paid or declared.
- Financial year-end changed to 31 December.
- Results not directly comparable to previous period.
- Unmodified audit opinion issued.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
